Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract
This is a phase II monocentric study of oxaliplatin (Ox) in combination with gemcitabine (Gem; GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.
Carcinoma, Transitional Cell
DRUG: gemcitabine, oxaliplatin
response rate (Response Evaluation Criteria in Solid Tumors [RECIST] criteria)
overall survival|disease free survival|toxicity
This is a phase II monocentric study of oxaliplatin (Ox) in combination with gemcitabine (Gem; GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.